Adam Mostafa
Equibles does not estimate personal net worth.
About Adam Mostafa
Earlier roles on record: CFO at X4 Pharmaceuticals, Inc (XFOR) until August 12, 2025. X4 Pharmaceuticals, Inc reported in an 8-K filed August 12, 2025 that Adam Mostafa resigned as Chief Financial Officer, Treasurer, Secretary and principal financial officer, effective August 12, 2025. The proxy statement of X4 Pharmaceuticals, Inc reports total compensation of $1,307,223 for Adam Mostafa in fiscal 2024, including a base salary of $510,000. Disclosed compensation is on record for 7 fiscal years. Adam Mostafa has spoken on 17 earnings calls across 1 company, most recently for X4 Pharmaceuticals, Inc on May 1, 2025. The companies whose calls Adam Mostafa spoke on are classified in the Healthcare sector.
“On August 11, 2025, Adam S. Mostafa notified the Board of his resignation as Chief Financial Officer, Treasurer, Secretary and principal financial officer of the Company, in each case, effective as of the Effective Time (the “CFO Separation”).”
Adam Mostafa on recent calls
“As we disclosed in the press release this morning, we ended the first quarter of 2025 with just under $90 million in cash and cash equivalents. We continue to believe that we have sufficient funds to support company operations into the first half of 2026.”
“At the end of the first quarter ended March 31, 2024, X4 had $81.6 million in cash, cash equivalents, restricted cash, and short-term marketable securities. We believe that these funds are sufficient to support company operations into 2025.”
“Having raised more than $87 million during 2023, comprised of a mix of equity and debt capital through an at-the-market pipe and through our expanded loan facility with Hercules, we ended 2023 with $115.2 million in cash and cash equivalents, short-term marketable securities, and restricted cash.”
“So regarding the label based on the previous label for GCSF, for example, we should see a label that addresses the reductions of infections in the patient populations that we include in this trial.”
“Concurrent with the announcement of the positive additional Phase III results for WHIM in mid-May, we were able to complete a PIPE financing priced at market, raising approximately $65 million in gross proceeds.”
Affiliation history
-
Start not stated–2025-08-12
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | X4 Pharmaceuticals, Inc (XFOR) | Chief Financial Officer, Treasurer and Secretary | $510,000 | $1,307,223 |
| 2023 | X4 Pharmaceuticals, Inc (XFOR) | Chief Financial Officer, Treasurer and Secretary | $486,192 | $1,152,848 |
| 2022 | X4 Pharmaceuticals, Inc (XFOR) | Chief Financial Officer, Treasurer and Secretary | $458,973 | $1,880,882 |
| 2021 | X4 Pharmaceuticals, Inc (XFOR) | Chief Financial Officer and Treasurer | $430,193 | $1,338,931 |
| 2020 | X4 Pharmaceuticals, Inc (XFOR) | Chief Financial Officer and Treasurer | $400,000 | $1,176,550 |
| 2019 | X4 Pharmaceuticals, Inc (XFOR) | Chief Financial Officer and Treasurer | $372,275 | $866,231 |
| 2018 | X4 Pharmaceuticals, Inc (XFOR) | Chief Financial Officer and Treasurer | $109,285 | $628,414 |